ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2032

Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation

Goh Murayama1, Asako Chiba 2, Ayako Makiyama 3, Taiga Kuga 4, Ken Yamaji 4, Naoto Tamura 4 and Sachiko Miyake 2, 1Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, 3Juntendo University School of Medicine, Tokyo, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autophagy and treatment, interferons, mTor, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interferona (IFNa) is increased and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes has been reported in patients with SLE. Plasmacytoid dendritic cells (pDCs) are thought as the main producer of IFNa upon activation of TLR pathway. However, IFNa producers by the stimulation of cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) in SLE still remains unknown. In this study, we investigated the IFNa producing capacity of myeloid cells under stimulation of cGAS-STING pathway.

Methods: Peripheral blood mononuclear cells from patients with SLE and healthy controls were stimulated with 2’3’c-GAMP, a stimulator of cGAS-STING pathway, or a TLR-7 agonist, imiquimod, and IFNa-producing capacity of myeloid cells was examined by intracellular cytokine staining and flow cytometry. The expression and co-localization of STING with TBK1 were examined by intracellular staining and flow cytometry or confocal microscopy. The effect of in vitro IFNa exposure on IFNa production and STING expression was examined. Monocytes were treated with rapamycin in vitro, and IFNa production and the expression of STING, pTBK1, IRF3 were examined.

Results: As previously reported, IFNa was produced from only pDCs upon activation of TLR7 pathway. However, IFNa was produced from monocytes, conventional dendritic cells (cDCs) and pDCs upon activation of cGAS-STING pathway. The frequency of IFNa-producing monocytes stimulated with 2’3’c-GAMP positively correlated with disease activity of SLE. The expression of STING and its co-localization with TBK1 were increased in lupus monocytes. Prior exposure to IFNa enhanced the IFNa-producing capacity of monocytes. Inhibition of mechanistic target of rapamycin (mTOR) pathway by using rapamycin suppressed IFNa production from monocytes and downregulated the enhanced expression of STING pathway.

Conclusion: We demonstrate that lupus monocytes are potent to produce IFNa in association with the augmentation of cGAS-STING pathway. Production of IFNa and enhancement of cGAS-STING pathway was suppressed by the inhibition of mTOR pathway. These findings indicate that enhanced IFNa from lupus monocytes owing to augmented STING pathway is associated with the pathogenesis of SLE. The blockade of the cGAS-STING pathway may serve as a promising therapeutic target for SLE.


Disclosure: G. Murayama, None; A. Chiba, None; A. Makiyama, None; T. Kuga, None; K. Yamaji, ASAHI KASEI PHARMA, 2, Astellas pharma, 2, 8, bristol myers, 8, Chugai Pharma, 2, Janssen Pharma, 8, Mitsubishi-Tanabe Pharma, 2, 8, Sanofi Pharma, 8, Takeda Pharma, 2; N. Tamura, AbbVie GK, 8, AbbVie pharma, 8, ASAHI KASEI MEDICAL, 2, ASAHI KASEI PHARMA, 2, astellas pharma, 2, 8, Astellas Pharma Inc., 2, 8, AYUMI PHARMA, 2, AYUMI Pharmaceutical Corporation, 2, bristol myers, 8, Bristol-Myers Squibb, 8, Chugai Phamaceutical Co. Ltd., 2, Chugai Pharma, 2, Eisai Co., Ltd., 2, Eisai Pharama, 2, Janssen Pharma, 8, Janssen Pharmaceutical K.K., 8, Mitsubishi Tanabe Pharma Corporation, 2, 8, Mitsubishi-Tanabe Pharma, 2, 8, Sanofi K.K., 8, Sanofi Pharma, 8, Takeda Pharma, 2, Takeda Pharmaceutical Company Ltd., 2; S. Miyake, Bristol myers squibb, 2, Bristol-Myers Squibb, 2, Pfizer, 2, Pfizer Japan Inc., 2, Taiho pharmaceutical, 8, TAIHO PHARMACEUTICAL CO., LTD., 8.

To cite this abstract in AMA style:

Murayama G, Chiba A, Makiyama A, Kuga T, Yamaji K, Tamura N, Miyake S. Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/enhanced-ifn-a-production-and-sting-pathway-in-monocytes-in-systemic-lupus-erythematosus-is-suppressed-by-the-inhibition-of-mtor-activation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhanced-ifn-a-production-and-sting-pathway-in-monocytes-in-systemic-lupus-erythematosus-is-suppressed-by-the-inhibition-of-mtor-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology